Overview OMO-1 in Solid Malignancies Status: Terminated Trial end date: 2020-05-25 Target enrollment: Participant gender: Summary This is a modular, first time in patient, open-label, multicentre study of OMO-1, administered orally, alone and in combination with anti-cancer treatments, in patients with locally advanced, unresectable or metastatic solid malignancies. Phase: Phase 1/Phase 2 Details Lead Sponsor: Octimet Oncology N.V.